Acute side effects of stereotactic radiotherapy and robotic radiosurgery: Experience with Cyberknife in the Oncology Hospital Medical National Centre SXXI [Efectos agudos de la radioterapia estereotáctica y de la radiocirugía robótica: Experiencia con el Cyberknife en el Hospital de Oncología del CMN SXXI]
Huerta Bahena J.,Hospital Of Oncologia Centro Medico Nacional Sxxi |
Leyva A.F.,Hospital Of Oncologia Centro Medico Nacional Sxxi |
Contreras A.P.,Hospital Of Oncologia Centro Medico Nacional Sxxi |
Vasquez A.A.,Hospital Of Oncologia Centro Medico Nacional Sxxi |
Tatenco F.M.,Hospital Of Oncologia Centro Medico Nacional Sxxi
Gaceta Mexicana de Oncologia | Year: 2015
Purpose: On July 2012, treatments with both intracranial and extracranial stereotactic radiot-herapy, using the Cyberknife system (Accuray Incorporated, Sunnyvale, California, USA), were started at the Robotic Radiosurgery Unit. This work is the report of the acute morbidity found throughout the first year of experience. Material and methods: An analysis was performed on the records of the first 132 consecutive patients with intra- and extracranial lesions, treated with the robotic non-isocentric linearaccelerator between July 2012 and June 2013. Intracranial radiosurgery (SRS) and stereotacticradiotherapy treatments were administered to 81 patients with 83 intracranial targets, and51 patients with 57 lesions received extracranial stereotactic radiotherapy treatments (SBRT).An analysis was made of acute morbidity occurring during the treatment, and within the 2subsequent weeks. Additionally, any symptom occurring within 6 weeks after the treatment was also assessed using the RTOG scale for acute morbidity Results: In the group of patients with intracranial target lesions, the most common tumour was pituitary adenoma, followed by meningioma, metastases, and schwannoma. Sixty-nine percent treated patients remained completely asymptomatic. The most frequently reported symptomwas dizziness, followed by headache. One patient experienced hypotension and asthenia, and 3other patients reported a combination of both these symptoms. Grade 2 morbidity was reportedin 6 of the 23 patients. One patient with a history of seizures required hospital admission dueto increased severity of the convulsive episodes. Pre-medication was given to 35 patients, outof which 21 remained asymptomatic. During the same period, 51 patients with 57 extracranial lesions were treated. The most common diagnosis was prostate cancer and the rest had oligometastases or primary lung orliver lesions. In this group of patients, 44% had no treatment-associated symptoms, whereas 12required symptomatic treatment. Grade 2 morbidity was reported in 12 patients. There were no cases of Grade 3 morbidity. Conclusions: Acute morbidity found within the first year of experience using intra- and extra-cranial stereotactic radiosurgery or radiotherapy is minimal and easily manageable, which demonstrates the safety of both these treatments. © 2015 Sociedad Mexicana de Oncología.